Cytokine-Based Therapies for Crohn's Disease — New Paradigms
- 11 November 2004
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 351 (20) , 2045-2048
- https://doi.org/10.1056/nejmp048253
Abstract
Crohn's disease is one of two idiopathic inflammatory bowel diseases that affect approximately 1 million people in North America. Despite important advances in diagnosis and treatment in recent years, the underlying cause of the disease remains unclear. As a result, the available therapies are not curative and may pose a substantial risk of side effects. A current theory regarding the pathogenesis of Crohn's disease suggests that there is an overly aggressive immune response against commensal bacteria in a genetically predisposed person. In this context, the activation of lymphocytes and the overexpression of inflammatory cytokines represent a common effector mechanism leading . . .Keywords
This publication has 5 references indexed in Scilit:
- Anti–Interleukin-12 Antibody for Active Crohn's DiseaseNew England Journal of Medicine, 2004
- Commentary: The role of the IL‐18 system and other members of the IL‐1R/TLR superfamily in innate mucosal immunity and the pathogenesis of inflammatory bowel disease: friend or foe?European Journal of Immunology, 2004
- TNF-αneutralization ameliorates the severity of murine Crohn's-like ileitis by abrogation of intestinal epithelial cell apoptosisProceedings of the National Academy of Sciences, 2003
- Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s diseaseGastroenterology, 2003
- Anti–interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in miceGastroenterology, 1999